Predictors of placebo response in pooled lamotrigine neuropathic pain clinical trials

Clinical Journal of Pain

Volumn 25, Issue 6, 2009, Pages 469-476

  Irizarry, Michael C ^a,d   Webb, David J ^a   Ali, Zahid ^b   Chizh, Boris A ^a   Gold, Michael ^c   Kinrade, Frances J ^c   Meisner, Paul D ^c   Blum, David ^c   Silver, Marianne T ^c   Weil, John G ^a  

^a GLAXOSMITHKLINE   (United States)

^b BioDelivery Sciences International   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d WW Epidemiology   (United States)

Author keywords

Diabetes; Neuropathic pain; Painful diabetic neuropathy; Placebo; Postherpetic neuralgia

Indexed keywords

GABAPENTIN; LAMOTRIGINE; PLACEBO; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROPATHIC PAIN; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM;

EID: 67649535292     PISSN: 07498047     EISSN: 15365409     Source Type: Journal    
DOI: 10.1097/AJP.0b013e31819ddded     Document Type: Article

References (27)

1. Rappaport BA. Current FDA policy on analgesic drug and biologic products development, 10th International Conference on the Mechanisms and Treatment of Neuropathic Pain. 2007.
2. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998;280:1831-1836.
3. Dworkin RH, Corbin AE, Young JP Jr, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebocontrolled trial. Neurology. 2003;60:1274-1283.
4. Freynhagen R, Strojek K, Griesing T, et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain. 2005;115:254-263.
5. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine versus placebo in patients with painful diabetic neuropathy. Pain. 2005;116:109-118.
6. Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. 2005;6:346-356.
7. Rosenstock J, Tuchman M, Lamoreaux L, et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain. 2004;110:628-638.
8. Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998;280:1837-1842.
9. Sabatowski R, Galvez R, Cherry DA, et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebocontrolled clinical trial. Pain. 2004;109:26-35.
10. Serpell MG. Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. Pain. 2002; 99:557-566.
11. van Seventer R, Feister HA, Young JP Jr, et al. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. Curr Med Res Opin. 2006;22:375-384.
12. Wernicke JF, Pritchett YL, D'Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006;67:1411-1420.
13. Silver M, Blum D, Grainger J, et al. Double-blind, placebocontrolled trial of lamotrigine in combination with other medications for neuropathic pain. J Pain Symptom Manage. 2007;34:446-454.
14. Vinik AI, Tuchman M, Safirstein B, et al. Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies. Pain. 2007;128:169-179.
15. Beydoun A, Shaibani A, Hopwood M, et al. Oxcarbazepine in painful diabetic neuropathy: results of a dose-ranging study. Acta Neurol Scand. 2006;113:395-404.
16. Dogra S, Beydoun S, Mazzola J, et al. Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo-controlled study. Eur J Pain. 2005;9:543-554.
17. Grosskopf J, Mazzola J, Wan Y, et al. A randomized, placebocontrolled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurol Scand. 2006;114:177-180.
18. Thienel U, Neto W, Schwabe SK, et al. Topiramate in painful diabetic polyneuropathy: findings from three double-blind placebo-controlled trials. Acta Neurol Scand. 2004;110: 221-231.
19. Dworkin RH, Katz J, Gitlin MJ. Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain. Neurology. 2005;65:S7-S19.
20. Turner JA, Deyo RA, Loeser JD, et al. The importance of placebo effects in pain treatment and research. JAMA. 1994; 271:1609-1614.
21. Farrar JT, Young JP Jr, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94:149-158.
22. Ziegler D, Pritchett YL, Wang F, et al. Impact of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic pain. Diabetes Care. 2007;30:664-669.
23. Katz J, Finnerup NB, Dworkin RH. Clinical trial outcome in neuropathic pain. Relationship to study characteristics. Neurology. 2007;70:263-272.
24. Quessy SN, Rowbotham MC. Placebo response in neuropathic pain trials. Pain. 2008;138:479-483.
25. Linde K, Witt CM, Streng A, et al. The impact of patient expectations on outcomes in four randomized controlled trials of acupuncture in patients with chronic pain. Pain. 2007; 128:264-271.
26. Finniss DG, Benedetti F. Mechanisms of the placebo response and their impact on clinical trials and clinical practice. Pain. 2005;114:3-6.
27. IMI Call Topics 2008. IMI-GB-018v2, April 24, 2008.